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Background. Fecal immunochemical tests (FITs) have been used for colorectal cancer (CRC) screening in several countries. There
is lack of information concerning diagnostic performances of this method in Brazil. Methods. Patients scheduled for elective
colonoscopy provided one stool sample one week before colonoscopy. The accuracy of a qualitative FIT for detection of CRC and
advanced adenomas was determined. Results. Overall 302 patients completed the study. Among them, 53.5%were high risk patients
referred for screening or surveillance. Nine (3%) CRCs and 11 (3.6%) advanced adenomas were detected by colonoscopy. Sensitivity
and specificity for CRC were, respectively, 88.9% and 87.6%. For advanced adenomas, sensitivity was 63.6% and specificity 87.6%.
Conclusion. Our results showed good sensitivity and specificity of the FIT for detecting advanced neoplasias. This method may be
a valuable tool for future screening programs in Brazil.
1. Introduction
Colorectal cancer (CRC) is a major cause of cancer morbidity
and mortality worldwide [1, 2]. Over the last years there has
been an increase in the reported incidence in Brazil, with
estimates for 2012 of 26.2 new cases/100.000 for men and
25.6/100.000 for women in the regions with higher incidence
rates [3]. In addition, analysis of CRC mortality in five
Brazilian capitals showed an increasing and constant trend
over the period of 1980–2009 [4].
The adenoma-carcinoma pathway is considered to be
responsible for the majority of CRC [5]. Recent data from a
long-term follow-up study showed that removal of adenoma-
tous polyps was associated with a 53% reduction in mortality
from CRC [6]. Considering the decrease in CRC incidence
and mortality associated with population screening for CRC
and precancerous lesions [7] guidelines in several countries
recommend that adults from the general population at
average risk should start screening at 50 years of age [1, 8, 9].
One of the proposed screening strategies is the survey with
high sensitivity (≥70%) fecal occult blood test (FOBT).
The traditional method to detect fecal occult blood has
been the guaiac-based test (G-FOBT) that detects the perox-
idase-like activity of hemoglobin. Although G-FOBT screen-
ing has been shown to reduce CRC incidence and mortality
[7], the sensitivity of this method in detecting CRC and
advanced adenomas has been shown to be low [10]. Another
disadvantage of the G-FOBT is that it requires dietary
restriction, since it is not specific for human blood and can
produce false-positive results when red meat and fruits or
vegetables containing peroxidase are ingested. In addition,
bleeding in the upper gastrointestinal tract secondary to
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aspirin and nonsteroidal anti-inflammatory drugs can also
produce false-positive tests.
More recently, the replacement of G-FOBT by immuno-
chemical fecal occult blood tests (FITs) has gained acceptance
in the literature. Many authors now recommend that FIT
should substitute G-FOBT for CRC screening [11]. FITs use
antibodies directed against human hemoglobin, are highly
specific for detecting human blood of colonic origin, and
thus are not affected by diet or medications. In addition,
several studies have demonstrated the superior diagnostic
performance of FITs in detecting both colonic adenomas and
cancers in comparison with standard G-FOBT [12–14].
Considering the lack of information regarding the diag-
nostic accuracy of FIT for advanced neoplasias in Brazil,
the aim of the present study was to assess prospectively the
sensitivity and specificity of a FIT in detecting CRC and
advanced adenomas using colonoscopy as the reference test.
2. Subjects and Methods
All consecutive patients scheduled for elective colonoscopy
at our university hospital endoscopy unit from July 2009 to
July 2010 were invited to bring a stool sample on the day
of the educational session about colonoscopy, which takes
place one week before the exam. All patients who underwent
colonoscopy and provided the stool sample were initially
included in the study. Those with incomplete colonoscopy
(which did not reach the cecum) and noncancerous bleeding
lesions at the time of colonoscopy, such as inflammatory
bowel disease or bleeding hemorrhoids, were excluded from
the analysis.
The study was approved by the Ethics Committee of our
institution.
2.1. Colonoscopy and Histopathological Analysis. Before col-
onoscopy a questionnaire containing clinical and epidemio-
logical data of the patient was completed. Colonoscopies were
performed or supervised by experienced endoscopists who
were blinded to the FIT results.
Polyps identified at the time of the exam were character-
ized by number, size, colonic location (proximal or distal to
the splenic flexure), and endoscopic appearance. All polyps
were removed and sent for histological analysis. Adenomas
were classified by number, size, location, and histologic
characteristics (tubular, tubulovillous, or villous).
Advanced adenoma was defined as either an adenoma
sized >1 cm, or with villous or tubulovillous pattern, or with
severe dysplasia [15].
For the purpose of analysis, in those cases with multiple
polyps classification was based on the most histologically
advanced lesion. Patients with diverticular diseases or non-
bleeding hemorrhoids were considered as having normal
colonoscopic findings.
2.2. Fecal Immunochemical Test. The FIT used in the current
study was the Feca-Cult One Step Test (Alamar Tecno
Cient´ıfica Ltda) which is an immunochromatographic test for
the qualitative determination of human hemoglobin in feces.
The manufacturer’s quoted cutoff hemoglobin concentration
Table 1: Demographic characteristics of the study population.
Characteristics 𝑁 (%)
Age in years (mean ± SD) 56 ± 14
<50 80 (26.5)
≥50 222 (73.5)
Gender
Females 194 (64.2)
Males 108 (35.8)
Personal history of CRC 80 (26.5)
Family history of CRC 36 (11.9)
is 0.2 𝜇gHb/mL. FIT was performed in a single sample taken
from a bowel movement one week before colonoscopy. All
tests were performed by the same investigator, and borderline
positive results (faint bands) were interpreted as positive.
2.3. Statistical Analysis. CRCs and advanced adenomas were
analysed separately. Continuous variables were reported as
mean ± SD and categorical variables were reported as
percentages. Comparisons of the results were performed
by the Mann-Whitney U test, Student’s t-test, and Fisher’s
exact test as appropriate. The diagnostic value of FIT for
detecting advanced adenomas and CRCs was assessed by
calculating the sensitivity and the specificity of the test. All
statistical analyses were carried out using SPSS version 20.0
for Windows (SPSS, Inc., Chicago, IL, USA). 𝑃 values < 0.05
were considered to be statistically significant.
3. Results
Overall 302 patients were included in the study (Figure 1).
Demographic characteristics of the study population are
summarized in Table 1. Mean age was 56 ± 14 years, 73.5%
were ≥50 years, and 64.2% were females.
Family history of CRC affecting one or two first-degree
relatives, diagnosed at age ≥50 years in all cases, was reported
by 36 (11.9%) patients.
The main indications for colonoscopy are shown in
Table 2. It can be seen that 42% of patients were referred for
colonoscopy because of symptoms, while 15.5% were high
risk patients referred for screening and 38% for surveillance
(polyps or previous surgery for CRC).
3.1. Colonoscopy Findings. Table 3 shows the colonoscopy
findings in the study population. CRC was found in 9
patients (3%) whereas advanced adenomas were detected in
11 patients (3.6%). The mean age of patients with CRC was
68 ± 10 years (53–78 years) and 89% were females. All cases
were adenocarcinomas, and 55.6% were well-differentiated
tumors. In 6 patients (66.7%) the tumor was located in the
distal colon. Two patients (22.2%) had a family history of
CRC. Eight of them had no previous colonoscopy, while one
had one adenoma in a previous examination.
The mean age of patients with advanced adenomas was
65 ± 13 years, and 63.6% were females. The location of the
lesions was the distal colon in 63.6% of the cases. Advanced
adenomas size ranged from 12 to 40mm, and the mean
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Scheduled for colonoscopy:
720
Scheduled for FIT:
470
FIT + colonoscopy:
362
Excluded: 108
Did not bring sample stool: 86
Did not come for colonoscopy: 12
Incomplete colonoscopy: 10
Could not be reached by 
telephone contact:
250
Excluded: 60
Active IBD: 25
Macroscopic bleeding: 35
Completed the study:
302
Figure 1: Flow chart of entry into the study.
Table 2: Main indications for colonoscopy in the study population.
Indications 𝑁 (%)
Symptoms 126 (42)
(i) Altered bowel habits 49 (38.8)
Diarrhea 27 (21.4)
Constipation 19 (15)
Alternating bowel habit 3 (2.4)
(ii) Abdominal pain 28 (22.2)
(iii) Anemia 16 (12.7)
(iv) Weight loss 9 (7.2)
(v) More than one of the symptoms above 16 (12.7)
(vi) Other symptoms 12 (6.4)
Screening (high risk patients) 47 (15.5)
(i) Inflammatory bowel disease 19 (40.4)
(ii) Family history of CRC 14 (29.8)
(iii) Previous G-FOBT + 6 (12.8)
(iv) Others 8 (17)
Surveillance 115 (38)
(i) Personal history of CRC 80 (69.6)
(ii) Polyps 35 (30.4)
Others 14 (4.5)
Total 302 (100)
Table 3: Colonoscopy findings in the study population.
Colonoscopy findings 𝑁 (%)
Normal 157 (52)
Polyps 73 (24)
Hyperplastic 27 (9)
Adenoma 35 (11.4)
Advanced adenoma 11 (3.6)
Diverticular disease 44 (14.6)
Inflamatory bowel disease 17 (5.7)
CRC 9 (3)
Others 2 (0.7)
Total 302 (100)
0
20
40
60
80
100
Normal Hyperplastic Adenomas Advanced
adenomas
CRC
Neg. FIT (%)
Pos. FIT (%)
Figure 2: FIT positivity in relation to the colonoscopic findings.
number of lesions was 3 ± 2. In 6 patients (55%), the ade-
nomas were of the villous type. Two patients underwent
colonoscopy because of polyps in previous exams. None of
them had family history of CRC.
3.2. FIT Results. In 50 patients (16.5%) the FIT was positive
(borderline positive in two cases). Figure 2 illustrates the
positivity rate of the test in relation to the colonoscopic
findings: 16.7% in patients with normal colonoscopy, 18.5%
in hyperplastic polyps, 5.5% in adenomas, 63.6% in advanced
adenomas, and 88.9% in CRC. There was a statistically
significant association (𝑃 = 0.001) between FIT positivity
and advanced adenomas and CRC.
3.3. FIT Performance. Table 4 shows the FIT performance in
detecting advanced adenomas and CRC. FIT sensitivity for
CRC was 88.9%, whereas specificity was 87.6%. For advanced
adenomas, the test sensitivity was 63.6% and the specificity
87.6%.
The predictive positive value (PPV) for CRC and
advanced adenoma was 18.6% and 16.7%, respectively, while
the correspondent negative predictive value (NPV) was
99.6% and 98.4%.
4. Discussion
In this colonoscopy-controlled study we assessed the sen-
sitivity and specificity of a qualitative FIT for detection of
CRC and advanced adenomas. The sensitivity of 88.9% and
specificity of 87.6% for CRC are within the range of 70–
100% sensitivity and 80–97% specificity reported in other
studies using FITs [16–18]. For example, three studies that
used the quantitative test OC-Sensor reported the sensitivity
and specificity for CRC as 80%/89% [19], 84.6%/89.8% [12],
and 100%/91.7% [18].
The qualitative test is a chromatographic method, and
the results are based on visual interpretation. Qualitative FIT
permits simple, on-site analysis, does not require specific
laboratory equipment, and therefore is less expensive than the
automated quantitative FIT. However, the use of qualitative
FITs has some disadvantages in relation to the quantitative
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Table 4: FIT performance in detecting CRC and advanced adenomas.
CRC (𝑛 = 9) Advanced adenomas (𝑛 = 11)
Sensitivity % (IC 95%) 88.9 (52–99) 63.6 (31–89)
Specificity % (IC 95%) 87.6 (83–91) 87.6 (83–91)
Positive predictive value % (IC 95%) 18.6 (8–33) 16.7 (7–31)
Negative predictive value % (IC 95%) 99.6 (97–99) 98.4 (96–99)
method. One of them is the possibility of interobserver
variation in the analysis of the results, particularly in those
cases of faint bands. The comparison of different qualitative
tests showed variations in the frequency of faint bands,
which may contribute to differences in the positivity results
among tests [20]. According to manufacturers, faint bands
should be regarded as borderline positive results. However,
the analysis of several qualitative tests showed that, for some
of them, borderline results should be rated negative rather
than positive [21].
In addition, previous studies have shown great differences
in the positivity rates of different qualitative FITs, which
were mainly related to different thresholds for detection of
hemoglobin in stool [21, 22]. At the same time, there was
a great variation in sensitivity and specificity for advanced
neoplasias, which was strongly related to the positivity rate
of the tests, indicating that lower cutoff values of fecal
hemoglobin required to generate a positive result would
render a higher test sensitivity. Therefore, test characteristics
such as low frequency of faint bands and low cutoff value of
fecal hemoglobin should be taken into account when select-
ing a qualitative test, reinforcing the importance of validation
studies before implementation of the test in population-based
screening.
Our study is also in agreement with those showing the
superior performance of FIT in detectingCRC in comparison
with advanced adenomas [23]. It has been proposed that
multiple rounds, such as annual FIT testing, are likely to
detect many of the lesions missed on initial screens before
they progress to CRC [24]. Computed simulations indicated
that five rounds of testing would increase the sensitivity for
advanced adenomas to the acceptable value of 81% [19].
Our results are based on the analysis of one fecal sample.
It has been suggested that FIT sensitivity increases with the
number of samples tested, such as 2- or 3-day analysis of fecal
samples, specially for advanced adenomas [25]. However,
other authors have shown that double sampling of FIT was
not superior to single sampling for detection of advanced
adenomas and CRC [26]. Further studies are necessary to
clarify this issue.
The design of the present study allowed the direct calcula-
tion of sensitivity and specificity of the FIT, since all patients
underwent colonoscopy. This is an advantage in relation to
the studies of screening populations, in which only subjects
who test positive are referred for colonoscopy. Sensitivity and
specificity are not influenced by the prevalence of disease, as
confirmed in a previous study showing similar FIT results in
screening and referral patients [27].
On the other hand, predictive values are determined by
sensitivity, specificity, and also the prevalence of the disease.
The prevalence of advanced neoplasias in our study group
composed of patients at average risk along with those at high
risk for CRC may be higher than that seen in average risk
screening population, and consequently, the test predictive
positive value may be lower in the screening population.
That means that a larger proportion of those with positive
screening tests will be found not to have the disease upon
colonoscopic examination.
A pilot study was held in a small city located in the
state of Sa˜o Paulo from 2006 to 2007, using a qualitative FIT
(Hemosure) for the screening of residents aged over 40 years
and at average risk for CRC [28]. Those with positive tests
were invited to undergo colonoscopic examination. Overall,
3,640 tests, 43.7% of the target population, were analyzed.
Results were positive in 390 (10.7%) exams. Colonoscopy
was performed in 212 patients with positive FIT, showing
polyps in 59 patients and adenocarcinoma in nine. All kits
and colonoscopes were donations, and therefore cost analysis
could not be performed.
Nowadays there is no public health policy for a nation-
wide CRC screening in Brazil. The implementation of a
screening program in our country is highly dependent
on public resources and therefore is critically affected by
economic aspects. For example, the health department of the
city of Sa˜o Paulo, the most populated city in Brazil, recently
concluded that at the moment it is not possible to implement
a population screening for CRC in the city [29]. Considering
the estimated target population (age 50–75 years) for 2011 as
about two million people and a 50% participation rate, the
use of biennial FIT (one sample) would require 550,000 kits
and 55,000 colonoscopic examinations per year (considering
the positivity rate of the test as 10%), which is more than
twice the number of examinations performed at present. No
cost-benefit analysis was performed. The evaluation has also
highlighted the need for pilot studies to assess feasibility
and cost effectiveness of regional screening programs. Other
aspects that should be addressed in future studies include the
choice between qualitative or quantitative FITs and annual or
biennial screening.
In conclusion, the FIT showed good sensitivity and
specificity for the detection of advanced neoplasia in our
study population, indicating that this method may be a
valuable tool for future screening programs in Brazil.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Gastroenterology Research and Practice 5
References
[1] J. A. Diaz and T. Slomka, “Colorectal cancer screening,” The
American Journal of LifestyleMedicine, vol. 6, no. 3, pp. 196–203,
2012.
[2] J. Ferlay, D. M. Parkin, and E. Steliarova-Foucher, “Estimates of
cancer incidence and mortality in Europe in 2008,” European
Journal of Cancer, vol. 46, no. 4, pp. 765–781, 2010.
[3] http://www.inca.gov.br/wps/wcm/connect/tiposdecancer/site/
home/colorretal.
[4] R. Mendonc¸a, M. Valada˜o, A. C. Couto, and S. Koifman,
“Trends of colorectal cancer mortality in five Brazilian capitals
from 1980 to 2009,” Cadernos Sau´de Coletiva, vol. 20, pp. 329–
335, 2012.
[5] M. J. Arends, “Pathways of colorectal carcinogenesis,” Applied
Immunohistochemistry and Molecular Morphology, vol. 21, pp.
97–102, 2013.
[6] A. G. Zauber, S. J. Winawer, M. J. O’Brien et al., “Colonoscopic
polypectomy and long-term prevention of colorectal-cancer
deaths,” The New England Journal of Medicine, vol. 366, no. 8,
pp. 687–696, 2012.
[7] J. Faivre, V. Dancourt, C. Lejeune et al., “Reduction in colorectal
cancer mortality by fecal occult blood screening in a French
controlled study,” Gastroenterology, vol. 126, no. 7, pp. 1674–
1680, 2004.
[8] U.S. Preventive Services Task Force, “Screening for colorectal
cancer: U.S. Preventive Services Task Force recommendation
statement,” Annals of Internal Medicine, vol. 149, no. 9, pp. 627–
637, 2008.
[9] D. J. Leddin, R. Enns, R. Hilsden et al., “Canadian association
of gastroenterology position statement on screening individuals
at average risk for developing colorectal cancer: 2010,”Canadian
Journal of Gastroenterology, vol. 24, no. 12, pp. 705–714, 2010.
[10] H. Bleiberg, “Hemoccult should no longer be used for the
screening of colorectal cancer,” Annals of Oncology, vol. 13, no.
1, pp. 44–46, 2002.
[11] K. L. Flitcroft, L. M. Irwig, S. M. Carter, G. P. Salkeld, and J. A.
Gillespie, “Colorectal cancer screening: why immunochemical
fecal occult blood tests may be the best option,” BMCGastroen-
terology, vol. 12, article 183, 2012.
[12] D. I. Park, S. Ryu, Y. H. Kim et al., “Comparison of guaiac-based
and quantitative immunochemical fecal occult blood testing
in a population at average risk undergoing colorectal cancer
screening,” The American Journal of Gastroenterology, vol. 105,
no. 9, pp. 2017–2025, 2010.
[13] A. Graser, P. Stieber, D. Nagel et al., “Comparison of CT colon-
ography, colonoscopy, sigmoidoscopy and faecal occult blood
tests for the detection of advanced adenoma in an average risk
population,” Gut, vol. 58, no. 2, pp. 241–248, 2009.
[14] L. Guittet, V. Bouvier, N. Mariotte et al., “Comparison of a
guaiac and an immunochemical faecal occult blood test for the
detection of colonic lesions according to lesion type and loca-
tion,” British Journal of Cancer, vol. 100, no. 8, pp. 1230–1235,
2009.
[15] S. J. Heitman, P. E. Ronksley, R. J. Hilsden, B. J. Manns, A.
Rostom, and B. R. Hemmelgarn, “Prevalence of adenomas and
colorectal cancer in average risk individuals: a systematic review
and meta-analysis,” Clinical Gastroenterology and Hepatology,
vol. 7, no. 12, pp. 1272–1278, 2009.
[16] T. R. deWijkerslooth, E.M. Stoop, P.M. Bossuyt et al., “Immun-
ochemical fecal occult blood testing is equally sensitive for
proximal and distal advanced neoplasia,”The American Journal
of Gastroenterology, vol. 107, no. 10, pp. 1570–1578, 2012.
[17] J. E. Allison, L. C. Sakoda, T. R. Levin et al., “Screening for col-
orectal neoplasms with new fecal occult blood tests: update
on performance characteristics,” Journal of the National Cancer
Institute, vol. 99, no. 19, pp. 1462–1470, 2007.
[18] R. Hazazi, P. Rozen, M. Leshno et al., “Can patients at high risk
for significant colorectal neoplasms and having normal quanti-
tative faecal occult blood test postpone elective colonoscopy?”
Alimentary Pharmacology and Therapeutics, vol. 31, no. 4, pp.
523–533, 2010.
[19] J. S. T. S. Droste, S. T. van Turenhout, F. A. Oort et al., “Faecal
immunochemical test accuracy in patients referred for surveil-
lance colonoscopy: amulti-centre cohort study,”BMCGastroen-
terology, vol. 12, article 94, 2012.
[20] B. Tannous, E. Lee-Lewandrowski, C. Sharples et al., “Compar-
ison of conventional guaiac to four immunochemical methods
for fecal occult blood testing: implications for clinical practice
in hospital and outpatient settings,” Clinica Chimica Acta, vol.
400, no. 1-2, pp. 120–122, 2009.
[21] H. Brenner, U. Haug, and S. Hundt, “Inter-test agreement
and quantitative cross-validation of immunochromatographi-
cal fecal occult blood tests,” International Journal of Cancer, vol.
127, no. 7, pp. 1643–1649, 2010.
[22] J. E. Allison, C. G. Fraser, S. P. Halloran, andG. P. Young, “Com-
paring fecal immunochemical tests: improved standardization
is needed,” Gastroenterology, vol. 142, no. 3, pp. 422–424, 2012.
[23] C. K. Wong, R. N. Fedorak, C. I. Prosser, M. E. Stewart, S. V.
van Zanten, and D. C. Sadowski, “The sensitivity and specificity
of guaiac and immunochemical fecal occult blood tests for the
detection of advanced colonic adenomas and cancer,” Interna-
tional Journal of Colorectal Disease, vol. 27, no. 12, pp. 1657–1664,
2012.
[24] M. J. Denters, M. Deutekom, P. M. Bossuyt, A. K. Stroobants,
P. Fockens, and E. Dekker, “Lower risk of advanced neoplasia
among patients with a previous negative result from a fecal test
for colorectal cancer,” Gastroenterology, vol. 142, no. 3, pp. 497–
504, 2012.
[25] A. H. C. van Roon, J. A.Wilschut, L. Hol et al., “Diagnostic yield
improves with collection of 2 samples in fecal immunochemical
test screening without affecting attendance,” Clinical Gastroen-
terology and Hepatology, vol. 9, no. 4, pp. 333–339, 2011.
[26] F. A. Oort, S. T. van Turenhout, V. M. H. Coupe´ et al., “Double
sampling of a faecal immunochemical test is not superior to
single sampling for detection of colorectal neoplasia: a colon-
oscopy controlled prospective cohort study,” BMC Cancer, vol.
11, article 434, 2011.
[27] S. T. van Turenhout, L. G. van Rossum, F. A. Oort et al., “Similar
fecal immunochemical test results in screening and referral
colorectal cancer,”World Journal of Gastroenterology, vol. 18, no.
38, pp. 5397–5403, 2012.
[28] R. O. Perez, I. Proscurshim, G. P. S. Julia˜o, M. Picolo, J. Gama-
Rodrigues, and A. Habr-Gama, “Instalac¸a˜o e resultados prelim-
inares de programa de rastreamento populacional de caˆncer
colorretal emmunic´ıpio brasileiro,”ABCD: Arquivos Brasileiros
de Cirurgia Digestiva, vol. 21, no. 1, pp. 12–15, 2008.
[29] Sa˜o Paulo (cidade), Secretaria Municipal da Sau´de, Coorde-
nac¸a˜o de Epidemiologia e Informac¸a˜o, Boletim CEInfo Ana´lise
no. 06, Secretaria Municipal da Sau´de, Sa˜o Paulo, Brazil, 2012.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
